Mitozolomide
Jump to navigation
Jump to search
Template:Short description Template:Drugbox Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.
Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]
References
Script error: No such module "Navbox".